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Abstract
Background: Switching between antiarrhythmic drugs is timed to minimize arrhythmia recurrence and adverse reactions.
Dronedarone and amiodarone have similar electrophysiological profiles; however, little is known about the optimal timing of
switching, given the long half-life of amiodarone. Methods: The ARTEMIS atrial fibrillation (AF) Loading and Long-term studies
evaluated switching patients with paroxysmal/persistent AF from amiodarone to dronedarone. Patients were randomized based
on the timing of the switch: immediate, after a 2-week, or after a 4-week washout of amiodarone. Patients who did not convert to
sinus rhythm after amiodarone loading underwent electrical cardioversion. The primary objectives were, for the Loading study, to
evaluate recurrence of AF 60 days; and for the Long-term study, to profile the pharmacokinetics of dronedarone and its
metabolite according to different timings of dronedarone initiation. Results: In ARTEMIS AF Loading, 176 were randomized
(planned 768) after a 28 + 2 days load of oral amiodarone. Atrial fibrillation recurrence trended less in the immediate switch
versus 4-week washout group (hazard ratio [HR] ¼ 0.65 [97.5% CI: 0.34-1.23]; P ¼ .14) and in the 2-week washout versus the 4-
week washout group (HR ¼ 0.75 [97.5% CI: 0.41-1.37]; P ¼ .32). In ARTEMIS AF Long-term, 108 patients were randomized
(planned 105). Pharmacokinetic analyses (n ¼ 97) showed no significant differences for dronedarone/SR35021 exposures in the 3
groups. Conclusion: The trial was terminated early due to poor recruitment and so our findings are limited by low numbers.
However, immediate switching from amiodarone to dronedarone appeared to be well tolerated and safe.
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Introduction
In order to optimize antiarrhythmic drug (AAD) therapy for
atrial fibrillation (AF), it may be necessary to switch from one
AAD to another.1 For most AADs, the switch is based on
stopping the drug for 5 half-lives before starting another.
Amiodarone is one of the most frequently prescribed AADs
for the treatment of AF in the world,2-4 but switching patients
from amiodarone to another drug is complicated by the drug’s
long half-life of 53 days.2 Furthermore, little is known about
the optimal timing for switching a patient from amiodarone to
dronedarone, a noniodinated benzofuran derivative that is
advocated for its shorter half-life and sparing of iodine-
related side effects.5
We report here the results from the ARTEMIS AF
“Loading” (A Randomized, international, multicenter, open-
label study to document optimal timing of initiation of drone-
darone TreatmEnt after conversion with loading dose of
aMIodarone in patients with perSistent Atrial Fibrillation
requiring conversion of AF) and ARTEMIS “Long-term” (A
Randomized, international, multicenter, open-label study to
document pharmacokinetics (PK) and optimal timing of initia-
tion of dronedarone TreatmEnt following long-term aMIodar-
one in patients with paroxysmal or perSistent AF whatever the
reason for the change of treatment) studies.
The aim of these 2 studies was to evaluate the efficacy and
safety of switching from amiodarone to dronedarone in patients
with AF who had either never previously received amiodarone
(Loading study) or who had 6 months previous exposure to
amiodarone (Long-term study). Both studies were intended to
provide data to guide optimal AAD use after amiodarone treat-
ment, including drug use in different subcategories of patients
with AF.
Methods and Materials
Design, Patients, and Data Collection
Loading and Long-Term Studies. In these 2 international, prospec-
tive, multicenter, open-label, randomized, controlled trials,
patients with either persistent AF requiring conversion to nor-
mal sinus rhythm (Loading study) or paroxysmal or persistent
AF (long-term study) were enrolled. Patients aged 18 years
who had provided written informed consent were eligible for
screening. Screening took place 12 weeks or 10 days prior
to randomization in the Loading and the Long-term studies,
respectively.
In both studies, key inclusion criteria at screening included
the following: a rate corrected QT interval using Bazett’s for-
mula (QTcB) of <500 milliseconds documented on a 12-lead
electrocardiogram (ECG) and 1 cardiovascular risk factor
(age >70 years, hypertension, diabetes, prior transient ischemic
attack, or left atrium diameter 50 mm). In the loading study,
following a change in label recommendations after study start
(regarding contraindications to dronedarone in the EU with
regard to heart failure after the PALbociclib CoLlaborative
Adjuvant Study [PALLAS]), patients with a history of and/or
current clinically overt heart failure (congestive heart failure
[CHF]), left ventricular systolic dysfunction, or unstable hemo-
dynamic conditions were excluded from the study; however,
some patients with CHF or left ventricular ejection fraction
<40% were already enrolled prior to this change and were
included. Patients in the Loading study must also have had
persistent AF >72 hours at screening (documented by an ECG
and for which cardioversion, AADs, and anticoagulation were
indicated), for which amiodarone had not been administered in
the prior 3 months. In the Long-term study, patients were eli-
gible for screening if they had paroxysmal or persistent AF and
had been receiving amiodarone for6 months (with at least the
last 2 months at a regimen of 200 mg/d). Patients who had been
receiving effective anticoagulation treatment or who required a
change of amiodarone treatment for any reason (excluding
those with major amiodarone-related toxicity, ie, interstitial
lung disease, thyroid, or hepatotoxicity) were also eligible for
inclusion in the Long-term study.
At randomization, patients must have been in sinus rhythm,
receiving effective anticoagulation (according to the American
College of Cardiology/American Heart Association/Heart
Rhythm Society treatment guidelines for AF),6 and have a
QTcB <500 milliseconds and PR interval <280 milliseconds
on a 12-lead ECG. In addition, patients in the Loading study
must have been receiving amiodarone for 28 days+ 2 days (at
visit 2 of the screening period, patients were given a loading
dose of amiodarone consisting of 600 mg daily [one 200 mg
tablet 3 times daily] for 1 week, 400 mg daily [one 200 mg
tablet twice daily] for 1 week, and 200 mg daily [one 200 mg
tablet once daily] for 2 weeks).
The main exclusion criteria were (1) contraindication to oral
anticoagulation, (2) documented AF after an acute condition
known to cause AF, (3) permanent AF (duration 6 months or
unknown), (4) bradycardia <50 bpm at rest on 12-lead ECG, (5)
CHF, (6) Wolff–Parkinson–White Syndrome, (7) previous his-
tory of amiodarone intolerance or toxicity, (8) previous abla-
tion for AF, (9) previous treatment with class I or class III
AADs (including sotalol) if taken less than 1 week before
screening, and (10) severe hepatic impairment (defined as
adverse events [AEs] in the system organ class hepatobiliary
disorders and standardized Medical Dictionary of Regulatory
Activities query liver-related investigations signs and symp-
toms). In the Loading study, patients with paroxysmal AF (in
whom cardioversion was not indicated) were also excluded.
Additional exclusion criteria in the Long-term study included
unstable angina pectoris (<7 days), myocardial infarction (<6
weeks), and a history of thyroid dysfunction.
Patients were randomized into 3 parallel groups (A, B, and
C) according to the timing of dronedarone initiation after the
loading dose or following discontinuation of long-term amio-
darone treatment (6 months). Group A patients were switched
to dronedarone 400 mg twice daily for 8 weeks immediately
after randomization, group B patients were switched to drone-
darone 400 mg twice daily for 6 weeks following a 2-week
amiodarone washout period, and group C patients were
switched to dronedarone 400 mg twice daily for 4 weeks
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following a 4-week amiodarone washout period (Figure 1).
Both drugs were supplied by Sanofi for the loading dose study.
The Loading study was conducted from September 2010 to
October 2011, while the Long-term study was conducted from
October 2010 to April 2012. Unfortunately, due to slow rates of
enrollment in the 2 studies, neither study would have been
completed within a reasonable and meaningful time frame.
Because of the difficulty in recruiting patients to the 2 studies,
the study sponsor, in agreement with the Steering Committee,
decided to stop the Loading study earlier than planned (on
October 20, 2011); no more patients were screened or rando-
mized on or after this date. However, following recalculation of
the sample size in the Long-term study, the target number of
patients was achieved.
Both studies were approved by the relevant institutional
review boards and performed in accordance with Good Clinical
Practice guidelines and the Declaration of Helsinki. The Clin-
icalTrials.gov identifiers are NCT01199081 (Loading study)
and NCT01140581 (Long-term study).
Pharmacokinetic Analysis. Plasma samples for quantification of
dronedarone and its metabolite SR35021were collected at base-
line (randomization), 3 hours after the first dronedarone dose,
and after 1, 2, and 4 weeks of treatment with dronedarone
(before the next dronedarone dose). The bioanalytical method
used for the analysis of dronedarone and SR35021 was a vali-
dated liquid chromatography–tandem mass spectrometry
method with a lower limit of quantification (LLOQ) of 0.5 ng/
mL for both compounds (Covance). The following exposures
were computed for dronedarone andSR35021: (1) themaximum
concentration (Cmax) of the first dronedarone intake on day 1; (2)
area under the concentration–time curve (AUC)24 hours in the
dosing interval of the first day of dronedarone intake; and (3)
AUC336 hours and AUC672 hours, the cumulated AUCs computed
over the first 2 and 4 weeks of the repeated dronedarone intake.
Study Objectives
Loading Study. The primary objective of the Loading studywas to
evaluate the rate of AF recurrence60 days after randomization
(defined as an episode of AF lasting 10 minutes, as indicated
by 2 consecutive 12-lead ECGs or transtelephonic ECG moni-
toring tracings recorded approximately 10 minutes apart, both
showing AF) according to different timings of initiation of dro-
nedarone. Due to a decrease in the sample size of the Loading
study as a result of slow recruitment rates, assessment of the
primary objective was expanded from 1 month to include the
entire study period, that is 60 days after randomization. Sec-
ondary objectives included (1) assessment of the safety of
switching from amiodarone to dronedarone and (2) assessment
of the overall safety profile of dronedarone. For the safety anal-
ysis, anAEwas defined as any untowardmedical occurrence in a
patient administered a pharmaceutical product that did not
necessarily have a causal relationship with this treatment, irre-
spective of any presumed relationship with the drug.
Figure 1. Study design. aAmiodarone initiation in Loading study, day - 28 + 2 days (at visit 2 of the screening period, patients were given a
loading dose of amiodarone consisting of 600 mg daily [one 200 mg tablet 3 times daily] for 1 week, 400 mg daily [one 200 mg tablet twice daily]
for 1 week, and 200 mg daily [one 200 mg tablet once daily] for 2 weeks). bElectrical cardioversion is allowed (after 7 days of amiodarone in
loading study) up to day 1 inclusive. cWith at least the last 2 months at a regimen of 200 mg/d.
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Long-term study. The primary objective of the Long-term study
was to explore the PK profile of dronedarone and its metabolite
SR35021 according to different timings of dronedarone initia-
tion. Secondary objectives included (1) evaluation of the rate of
AF recurrence 60 days after randomization (based on adju-
dicated ECG data and defined as the time from day 1 [rando-
mization] to the date of ECG where the first AF recurrence was
observed), (2) exploration of the potential PK interaction
between dronedarone and amiodarone, (3) assessment of the
safety of switching from amiodarone to dronedarone, and (4)
assessment of the overall safety profile of dronedarone. Recur-
rence of AF was defined as an episode of AF lasting 10
minutes and indicated by 2 consecutive 12-lead ECG tracings
recorded approximately 10 minutes apart. Patients who did not
experience AF recurrence were censored at day 61 or at the end
of the study if this date was prior to day 60; patients who
discontinued prematurely were censored at the day of discon-
tinuation. For the safety analysis, AEs were defined as in the
Loading study.
Statistical Analysis
Loading study. Based on the original efficacy analysis, and in
order to show a reduction of AF recurrence after 1 month by
36.5% in group A (and group B) compared with group C, with
an a level of 2.5% (2-sided tests) and 80% power, it was esti-
mated that 256 evaluable patients per treatment group were
required. Taking into account an expected screening failure
rate of 10%, 860 patients should be screened in order to rando-
mize 768 patients (256 per arm). However, due to the low
enrollment rate, only 176 patients were randomized. This fig-
ure was significantly smaller than originally estimated.
For the main efficacy analysis, log-rank tests were used to
compare group A versus group C and group B versus group C;
significance levels for each comparison were set at 0.025
(2-sided), in order to maintain a global a level of .05. A Cox
proportional hazard model was used to calculate hazard ratios
(HRs), with 2-sided 97.5% CIs. The primary analysis popula-
tion was the intent-to-treat population, which consisted of all
randomized patients.
Long-term study.With an estimated non-evaluability rate of 10%
before and 10% after randomization, 165 patients were planned
to be screened in order to randomize 147 (49 in each group).
However, due to a slow enrollment rate, the protocol was
amended (November 8, 2011); following this amendment 147
patients were planned to be screened in order to randomize 105
patients (35 in each group), using an estimated non-evaluability
rate of 30% and in order to achieve a maximal imprecision of
20%.
For the main efficacy analysis, a non-stratified log-rank test
was used to compare group A with group C and group B with
group C; significance levels for each comparison were set at
0.025 (2-sided), in order to maintain a global a level of .05
(2-sided). Cumulative incidence functions were calculated using
a nonparametric Kaplan–Meier estimate. A Cox proportional
hazard model was used to calculate HR, with 2-sided 97.5% CIs.
Pharmacokinetic analysis. Estimation of dronedarone and
SR35021 individual exposure parameters was only possible
through a Bayesian process, due to the limited sample size.
The Bayesian analysis was performed with the NONMEM
computer program (version 7.2) running on a LINUX cluster
of multiprocessor computers.7 A previously developed popula-
tion pharmacokinetics (PopPK) model was applied to the data
set, using its population parameter estimates as prior estimates
for the assessment of individual parameters and concentration
predictions for the patients from the ARTEMIS AF study. Due
to the complexity of the PopPK model (simultaneously fitting
dronedarone and SR35021 concentrations), the first-order esti-
mation method was used throughout the whole modeling pro-
cess. For each patient, individual PK parameter estimates were
made from the obtained population parameters.
Dronedarone was given immediately, 2 weeks/336 hours or
4 weeks/672 hours after amiodarone cessation; however, the
relative time between the last amiodarone dose and the first
dronedarone administration was variable between patients. Due
to the limited sample size and to avoid any loss of information,
for the purposes of the plots, all dosing times before 48 hours
were considered as “immediately,” all times between 48 and
408 hours (17 days) as “2 weeks,” and all times >408 hours as
“4 weeks.”
Results
Study Population Loading Study
In total, 403 patients were screened from 49 sites in 16 coun-
tries across Europe, Asia-Pacific, and South America (Austra-
lia, Austria, Estonia, Finland, France, Germany, Israel, Italy,
the Republic of Korea, Mexico, the Netherlands, Portugal,
Spain, Switzerland, Taiwan, and the UK). Due to slow enroll-
ment, the study was stopped by the sponsor prior to reaching
the planned sample size. Overall, 176 patients were rando-
mized: 58, 59, and 59 into groups A, B, and C, respectively
(Figure 1; Appendix Table 1). One hundred and forty-eight
patients completed treatment (51, 53, and 44 in groups A, B,
and C, respectively). Baseline demographics and cardiovascu-
lar parameters are shown in Table 1.
Study Population Long-Term Study
In total, 154 patients were screened from 29 sites in 7 countries
across Europe, North, and South America (Colombia, the
Czech Republic, Denmark, France, Germany, Mexico, and
Spain). Overall, 108 patients were randomized: 37, 38, and
33 into groups A, B, and C, respectively (Figure 1; Appendix
Table 2). Eighty-six patients completed treatment (35, 25, and
26 patients in groups A, B, and C, respectively). Baseline
demographics and cardiovascular parameters are shown in
Table 2.
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Table 1. Baseline Demographics and Cardiovascular Parameters in the Loading Study (Randomized Population).
A
Immediate
n ¼ 58
B
2-Week WO
n ¼ 59
C
4-Week WO
n ¼ 59
Total
N ¼ 176
Female, n (%) 12 (20.7) 14 (23.7) 16 (27.1) 42 (23.9)
Age, mean years (SD) 66.4 (11.1) 66.0 (10.2) 66.4 (10.7) 66.2 (10.6)
BMI (kg/m2), n 57 58 59 174
Mean (SD) 28.8 (4.3) 29.2 (6.3) 29.4 (3.9) 29.1 (4.9)
Median 28.7 27.7 29.6 28.8
(Q1; Q3) (25.9; 31.2) (24.7; 32.8) (26.4; 31.9) (25.9; 31.9)
CHF, n (%) 12 (20.7) 20 (33.9) 20 (33.9) 52 (29.5)
NYHA I 5 (41.7) 10 (50.0) 11 (55.0) 26 (50.0)
NYHA II 7 (58.3) 10 (50.0) 9 (45.0) 26 (50.0)
NYHA III-IV 0 0 0 0
Left atrium diameter (mm), n 46 49 54 149
Mean (SD) 46.2 (6.5) 45.3 (6.3) 46.0 (6.8) 45.8 (6.5)
LVEF, na 41 48 50 139
<40%, n (%) 2 (4.9) 2 (4.2) 2 (4.0) 6 (4.3)
40%, n (%) 39 (95.1) 46 (95.8) 48 (96.0) 133 (95.7)
Abbreviations: BMI, body mass index; CHF, congestive heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; WO, washout.
aFollowing a change in prescription recommendations after study start, patients with a history of and/or current heart failure, left ventricular systolic dysfunction,
or unstable hemodynamic conditions were excluded from the study; however, some patients with CHF or LVEF <40% were already enrolled prior to this change.
Table 2. Baseline Demographics and Cardiovascular Parameters in the Long-term Study (Randomized Population).
A
Immediate
n ¼ 37
B
2-Week WO
n ¼ 38
C
4-Week WO
n ¼ 33
Total
N ¼ 108
Female, n (%) 19 (51.4) 20 (52.6) 10 (30.3) 49 (45.4)
Age, mean years (SD) 68.0 (9.9) 68.0 (10.7) 66.4 (8.7) 67.5 (9.8)
BMI (kg/m2), n 37 38 33 108
Mean (SD) 30.9 (5.7) 29.4 (5.9) 30.6 (5.8) 30.3 (5.8)
Median 30.1 28.6 29.7 29.3
(Q1; Q3) (26.3; 35.1) (25.7; 31.7) (27.3; 32.1) (26.4; 32.9)
Type of AF, n (%)
Paroxysmal 28 (75.7) 29 (76.3) 23 (69.7) 80 (74.1)
Persistent 9 (24.3) 9 (23.7) 10 (30.3) 28 (25.9)
Time since the first known episode of
AF at screening (months), n
29 33 26 88
Mean (SD) 36.0 (41.2) 37.1 (36.4) 27.6 (26.9) 33.9 (35.5)
Median 18.6 24.5 14.9 17.2
(Q1; Q3) (10.4; 37.0) (10.0; 54.8) (10.7; 42.4) (10.2; 50.8)
Time since the onset of current AF
episode (days), n
1 3 1 5
Mean (SD) 30.0 ( ) 6.0 (0.7) 31.0 ( ) 15.0 (14.0)
Median 30.0 1.0 31.0 16.0
(Q1; Q3) (30.0; 30.0) (1.0; 16.0) (31.0; 31.0) (1.0; 30.0)
CHF, n (%) 3 (8.1) 7 (18.4) 2 (6.1) 12 (11.1)
NYHA I 1 (33.3) 2 (28.6) 2 (100.0) 5 (41.7)
NYHA II 2 (66.7) 5 (71.4) 0 7 (58.3)
NYHA III-IV 0 0 0 0
Left atrium diameter (mm), n 25 27 24 76
Mean (SD) 45.3 (7.4) 47.3 (8.8) 45.4 (7.6) 46.0 (7.9)
LVEF, n (%) 27 31 26 84
<40% 0 3 (9.7) 0 3 (3.6)
40% 27 (100) 28 (90.3) 26 (100) 81 (96.4)
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CHF, congestive heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; WO, washout.
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Efficacy
Loading study. There was a non-statistically significant decrease
in AF recurrence (60 days after randomization) of 35.3% (HR
¼ 0.65 [97.5% CI: 0.341-1.225]; P ¼ .14) in the immediate
(group A) compared with the 4-week washout group (group C).
For the 2-week washout group (group B), there was a non-
statistically significant 24.7% decrease in AF recurrence (HR
¼ 0.753 [97.5% CI: 0.413-1.374]; P ¼ .32) compared with the
4-week washout group (group C; Figure 2A).
Mean (SD) heart rates remained virtually unchanged between
baseline and end of treatment (59.9 [9.7] and 62.0 [11.4], respec-
tively). Overall, changes were similar across the 3 treatment
groups. At baseline, rates were 59.8 (10.2) bpm for group A,
60.6 (9.4) bpm for group B, and 59.3 (9.8) bpm for group C. At
the endof treatment, rateswere63.4 (13.3) bpmfor groupA,61.9
(9.7) bpm for group B, and 60.5 (11.0) bpm for group C.
Long-term study. There were no significant differences in risks
of AF recurrence (60 days after randomization) among the 3
treatment groups (Figure 2B). Compared with the 4-week
washout group (group C), there was a nonsignificant increase
in AF recurrence of 6.3% in the immediate group (group A;
P ¼ .93). However, there was an 88.5% increased risk of AF
recurrence in the 2-week washout group (group B) compared
with the 4-week group (group C); again, this difference was not
statistically significant (P ¼ .26).
The mean heart rate showed normal variation throughout the
treatment period and across the 3 treatment groups, with a total
mean (SD) of 63.2 (9.2) bpm at baseline and 62.5 (12.3) bpm at
the end of treatment. Overall, changes were similar across the 3
treatment groups. At baseline, rates were 62.3 (8.0) bpm for
group A, 63.4 (10.4) bpm for group B, and 64.4 (9.4) bpm for
group C. At the end of treatment, rates were 63.0 (13.8) bpm
for group A, 60.7 (11.5) bpm for group B, and 63.7 (11.1) bpm
for group C.
Pharmacokinetics
Long-term study. The data set comprised the 97 patients who had
at least 1 sample of either dronedarone or SR35021 above the
LLOQ, for a total of 729 samples (365 for dronedarone and 364
for SR35021). The mean (+SD) age of the Bayesian data set
was 67.3 (10.1) years. In total, 48.5% were male and 74.2%
were Caucasian.
Dronedarone andSR35021 exposure values (Cmax) at the first
dronedarone intake on day 1 are shown in Figure 3A. The lowest
values were observed in this “immediate” group (group A),
while the highest values were seen in the 2-week washout group
(groupB; Table 3). As shownby theAUCs, therewas a tendency
toward higher values for both dronedarone and SR35021 expo-
sures in the 2-week washout group (group B), while the lowest
values were observed in the 4-week washout group (group C;
Figure 3B-D). Descriptive statistics on individual exposure val-
ues of dronedarone and SR35021 are presented separately for
each treatment group in Table 3 (ie, dronedarone given imme-
diately, 2 or 4 weeks after amiodarone cessation).
Safety
Loading study. Overall, there were no significant differences
among the 3 treatment groups in the risk of bradycardia
(defined as a heart rate at rest <50 bpm; group A vs group C,
P ¼ .55; group B vs group C, P ¼ .49) or tachycardia (defined
as heart rate at rest >90 bpm; group A vs group C, P ¼ .54;
group B vs group C, P ¼ .12). In total, 20, 22, and 11 patients
(20.1, 27.1, and 25.0 patient-months) experienced an AE in the
immediate-switch group (group A), 2-week washout (group B),
and 4-week washout group (group C), respectively (Table 4). In
total, 53 patients had a treatment-emergent AE (TEAE); 9 of
these had a serious TEAE. Across the 3 groups, 4 (1.8 patient-
months) patients permanently discontinued dronedarone treat-
ment due to a TEAE (2.0, 1.3, and 2.3 patient-months in the
immediate, 2-week, and 4-week washout groups, respectively).
Treatment-emergent AEs leading to permanent dronedarone
discontinuation included dizziness and tremor in group A, syn-
cope in group B, and chronotropic incompetence in group C.
Overall, there was a similar incidence of potentially clini-
cally significant abnormalities among the 3 treatment groups
Figure 2. A, First recurrence of AF 60 days after randomization in
the Loading study (ITT population), and (B) First recurrence of AF
60 days after randomization in the Long-term study (ITT popula-
tion). Cumulative incidence function with Kaplan–Meier estimates,
based on adjudicated data. AF indicates atrial fibrillation; ITT, intent-
to-treat.
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Figure 3. (A) Dronedarone and SR35021 Cmax calculated at the first dronedarone intake (Long-term study Bayesian data set), (B) dronedarone
and SR35021 AUC24 hours at the first day of dronedarone administration (Long-term study Bayesian data set), (C) dronedarone and SR35021
AUC336 hours calculated over the first 2 weeks of dronedarone intake (Long-term study Bayesian data set), and (D) dronedarone and SR35021
AUC672 hours calculated over the first 4 weeks of dronedarone intake (Long-term study Bayesian data set). White dots represent individual
values; black dots and error bars are mean values+ SD. The horizontal error bars quantify the variation in the timing of dronedarone initiation
after amiodarone discontinuation in each group. The vertical error bars describe the variation in dronedarone concentrations. AUC indicates
area under the curve; Cmax, maximum concentration.
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with the exception of an increased PR interval; an increased PR
interval was more frequently reported in the immediate switch
group (15.2%) compared with the 2-week washout (4.8%) and
4-week washout (3.4%) groups. While not statistically signif-
icant, during the dronedarone period, QTcB500 milliseconds
at any visit was greater in the immediate-switch group (group
A; 7/58, 12.1%) compared with both the 2-week (group B; 3/
57, 5.3%; P ¼ .53) and 4-week washout (group C; 4/48, 8.3%;
P ¼ .93) groups, respectively.
Long-term study. Patients in the 2-week washout group (group B)
had a significantly higher risk of bradycardia compared with
those in the 4-week washout group (group C; HR ¼ 6.15
[97.5% CI: 1.095-34.533]; P ¼ .01). However, there was no
significant difference in risk of bradycardia between the imme-
diate dronedarone group (group A) and the 4-week washout
group (group C; P ¼ .19) or risk of tachycardia among the 3
treatment groups (group A vs group C, P ¼ .33; group B vs
group C, P ¼ .26).
Overall 15, 14, and 9 patients (22.5, 34.3, and 35.0 patient-
months) experienced an AE in the immediate-switch group
(group A), 2-week washout group (group B), and 4-week wash-
out group (group C), respectively (Table 5). In total, 38 patients
reported 1 TEAE, 5 of these had 1 serious TEAE, and 2
reported a serious TEAE leading to hospitalization (1 patient
was hospitalized for pneumonia with symptoms of fever and 1
patient experienced worsening of rectal pain and stool inconti-
nence). Across the 3 groups, 8 (6.0 patient-months) patients
permanently discontinued dronedarone treatment due to a
TEAE. Although more patients in the 2-week washout group
(group B; n ¼ 6 [14.7 patient-months]) had a TEAE leading to
permanent discontinuation compared with the immediate-
switch (group A) and 4-week washout (group C) groups (n ¼
Table 3. Mean, CV%, Median, and 5th and 95th Percentiles of Individual Exposure Values of Dronedarone and SR35021 (Long-Term Study
Bayesian Data Set).
Parameter
Dronedarone SR35021
Mean (CV%),
geometric mean
Median,
5th-95th percentiles
Mean (CV%),
geometric mean
Median,
5th-95th percentiles
Group A—dronedarone given 0-48 hours after amiodarone cessation (n ¼ 33)
AUC24 hours (ng.h/mL) 1098 (25.8), 1070 1022, 828-1772 676 (28.9), 653 623, 482-1067
AUC336 hours (ng.h/mL) 37 068 (22.7), 36 135 34 540, 25 312-52 320 24 158 (24.4), 23 469 23 909, 14 846-34 485
AUC672 hours (ng.h/mL) 78 773 (24.3), 76 524 72 730, 52 491-11 3874 51 330 (24.8), 49 805 51 675, 31 044-73 522
Cmax on day 1 (ng/mL) 43.5 (46.4), 40.2 34.0, 28.2-90.8 26.4 (41.0), 24.8 23.7, 16.8-44.8
Group B—dronedarone given 48-408 hours after amiodarone cessation (n ¼ 36)
AUC24 hours (ng.h/mL) 1291 (32.8), 1232 1151, 818-2155 721 (35.9), 686 639, 488-268
AUC336 hours (ng.h/mL) 42 452 (34.6), 39 942 39 059, 21 219-68 130 25 202 (40.4), 23 472 21 342, 14 413-48 905
AUC672 hours (ng.h/mL) 91 808 (37.7), 85 504 82 917, 43 735-153 716 54 627 (43.5), 50 351 45 106, 30 481-110 330
Cmax on day 1 (ng/mL) 57.5 (46.0), 52.2 51.6, 30.7-108 30.9 (45.9), 28.4 26.8, 17.2-61.5
Group C—dronedarone given >408 hours after amiodarone cessation (n ¼ 28)
AUC24 hours (ng.h/mL) 1181 (48.9), 1097 998, 739-2317 695 (50.0), 643 576, 446-1480
AUC336 hours (ng.h/mL) 33 662 (39.2), 31 398 29 398, 17 896-59 105 20 771 (38.0), 19 449 17 263, 12 074-33 166
AUC672 hours (ng.h/mL) 71 191 (41.5), 65 914 61 319, 36 682-131 359 43 953 (39.7), 40 908 36 266, 24 963-71 641
Cmax on day 1 (ng/mL) 52.1 (56.2), 46.6 41.2, 28.9-113 29.8 (57.6), 26.7 25.3, 16.1-70.2
Abbreviations: AUC, area under the curve; Cmax, maximum concentration; CV, coefficient of variation.
Table 4. Safety Overview During the Dronedarone Period in the Loading Study (Randomized and Treated Population).
A
Immediate
n ¼ 58
B
2-Week WO
n ¼ 57
C
4-Week WO
n ¼ 48
TEAEs, n (patient-months) 20 (20.1) 22 (27.7) 11 (25.0)
Serious TEAEs, n (patient-months) 3 (3.0) 4 (5.0) 2 (4.5)
Serious TEAEs leading to hospitalization, n (patient-months) 1 (1.0) 1 (1.3) (0.0)
TEAEs leading to permanent treatment discontinuation, n (patient-months) 2 (2.0) 1 (1.3) 1 (2.3)
TEAEs leading to death, n (patient-months) (0.0) (0.0) (0.0)
Congestive heart failure, n (patient-months)a 1 (1.0) (0.0) 1 (2.3)
Peripheral neuropathy (including optic neuropathy), n (patient-months)a 1 (1.0) 1 (1.3) (0.0)
Hepatic event, n (patient-months)a,b (0.0) 1 (1.3) 3 (6.8)
Abbreviations: TEAE, treatment-emergent adverse event; WO, washout. Patient-months ¼ number of patients with at least 1 TEAE in 100 patient-months.
aAdverse event of special interest (as per the narrow Standardized Medical Dictionary of Regulatory Activity Query, version 14.1).
bIncrease in alanine transaminase.
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2 [3.0 patient-months] and n ¼ 0 [0 patient-months], respec-
tively), there were no other important differences overall in
AE profiles among the 3 treatment groups (Table 5).
Treatment-emergent AEs leading to permanent dronedarone
discontinuation included arrhythmia, cardiac failure, burning
sensation, diplopia, vision blurred, and syncope in group A and
abdominal pain upper, nausea, tinnitus, pruritus, hypersensitiv-
ity, asthenia, and erythema in group B.
Discussion
Amiodarone is currently the most widely used AAD for the
maintenance of sinus rhythm. However, amiodarone has a very
long half-life and tissue accumulation, potentially leading to
severe organ toxicities and cancer with long-term use in men.
Measurable PK and pharmacodynamic effects can be detected
several weeks after amiodarone treatment discontinuation. Dro-
nedarone, a benzofuran derivative demonstrating electrophysio-
logical characteristics belonging to all four Vaughan-Williams
classes, is devoid of the iodine moiety and has a methane sulfo-
nyl group that reduces its lipophilicity and likelihood of accu-
mulation in tissue.8 Clinical studies have demonstrated the
favorable safety profile of dronedarone in patients with parox-
ysmal or persistent AF and the lower risk for amiodarone-like
organ toxicity.9 Patients with AF who have already been
exposed to amiodarone might be eligible for treatment with
dronedarone for safety reasons and, potentially, to target clinical
outcome benefits as shown in the ATHENA study.10
Dronedarone has a low propensity for medical conversion of
persistent AF to sinus rhythm,11 whereas oral amiodarone may
convert up to 25% of persistent AF patients after several weeks
of loading.12 In addition, evidence suggests that persistent AF
patients treated with amiodarone have a good probability of
preserving sinus rhythm following termination of the arrhyth-
mia.12 As such, amiodarone is commonly used for this purpose.
Given that amiodarone is also effective in preventing early AF
recurrences post-cardioversion, the clinical approach of load-
ing with amiodarone (to optimize cardioversion outcomes),
then switching to dronedarone (for long-term benefits), could
become customary in clinical practice. Both drugs have similar
multichannel blocking effects and have an extremely low risk
of causing torsades de pointes. In the clinical trial program of
patients with nonpermanent AF, dronedarone demonstrated a
similar risk of ventricular pro-arrhythmia as placebo,9-11 and in
a real-world analysis of all AF patients in the Swedish Patient
registry (2010-2015) dronedarone was the only AAD with
lower risk of ventricular pro-arrhythmia than sotalol.13
However, physiciansmay be concerned about potential addi-
tive safety issues such as bradycardia, QT interval prolongation,
and an increase in the PR interval if the 2 drugs are given in
combination. Thus, in order to acquire a better knowledge of
dronedarone’s behavior following a switch from amiodarone,
this phase IV clinical study, ARTEMIS AF, was performed to
evaluate the impact of amiodarone on dronedarone.
The ARTEMIS AF Loading study involved administration of
dronedarone to patients who had persistent AF requiring conver-
sion at 3 different intervals after administration of a loading dose
of amiodarone. Although patients may not have been fully
loaded, they all received the same cumulative loading dose of
nearly 10 g of drug over 4 weeks. ARTEMIS AF loading was
designed to specifically and prospectively evaluate the efficacy
and safety of the immediate change from a loading dose of
amiodarone to long-term dronedarone treatment in comparison
with initiation after a 2-week or a 4-week amiodarone washout
period. Unfortunately, due to slow rates of enrollment, the study
would not have been completed within a reasonable and mean-
ingful time frame. As such, only 176 patients were randomized
out of the original 768 planned. While 148 (84.1%) of rando-
mized patients completed the study, the final sample size was not
sufficient to provide robust efficacy data.
In the Loading study, there was a nonsignificant numerical
trend for a reduction in AF recurrence in the immediate-
treatment group and the 2-week washout group compared with
the 4-week washout group. The overall safety profile was sim-
ilar in all 3 treatment groups, with no increase in AEs seen in
the absence of a washout period. Although in this small cohort
of patients the tolerability of a rapid switch was acceptable, the
decision of when to start dronedarone after the discontinuation
of amiodarone should be made on an individual basis, taking
into account each patient’s characteristics.
Table 5. Safety Overview During the Dronedarone Period in the Long-term Study (Randomized and Treated Population).a
A
Immediate
n ¼ 37
B
2-Week WO
n ¼ 34
C
4-Week WO
n ¼ 27
TEAEs, n (patient-months) 15 (22.5) 14 (34.3) 9 (35.0)
Serious TEAEs, n (patient-months) 3 (4.5) 1 (2.4) 1 (3.9)
Serious TEAEs leading to hospitalization, n (patient-months)A 1 (1.5) (0.0) 1 (3.9)
TEAEs leading to permanent treatment discontinuation, n (patient-months) 2 (3.0) 6 (14.7) (0.0)
TEAEs leading to death, n (patient-months) (0.0) (0.0) (0.0)
Congestive heart failure, n (patient-months)b 1 (1.5) 1 (2.4) (0.0)
Peripheral neuropathy (including optic neuropathy), n (patient-months)b 1 (1.5) (0.0) (0.0)
Hepatic event, n (patient-months)b,c 1 (1.5) 1 (2.4) (0.0)
Abbreviations: TEAE, treatment-emergent adverse event; WO, washout. Patient-months ¼ number of patients with at least 1 TEAE in 100 patient-months.
aAdverse event of special interest (as per the narrow Standardized Medical Dictionary of Regulatory Activity Query, version 14.1)
bIncrease in alanine transaminase.
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Similarly, in the ARTEMIS AF Long-term study, while the
primary objective was to explore dronedarone and SR35021
PK profiles according to different timings of dronedarone
initiation, considering the low number of patients available in
each study group, it is not possible to confirm whether the
differences in dronedarone/SR35021 exposures from 1 treat-
ment group to another are significant. In the Long-term study,
the PK data showed that surprisingly, there was a tendency
toward higher values for dronedarone and SR35021 exposures
in the 2-week washout group, with the lowest values observed
in the 4-week washout group. This was mainly visible on
cumulative AUCs computed after 2 or 4 weeks of dronedarone
intake (Figure 3) and is in accordance with the dronedarone
concentrations observed in the ARTEMIS AF study. Similar
trends were also observed for amiodarone. Superficially, such
observations could suggest a possible drug–drug interaction
between dronedarone and amiodarone. However, this possibil-
ity can likely be discarded because observed amiodarone con-
centrations collected before any dronedarone intake (on visit 3)
were also higher in the 2-week washout group compared with
the immediate dronedarone and 4-week washout groups (med-
ian values of 828 vs 605 and 616 ng/mL, respectively).
The higher amiodarone concentrations observed before any
dronedarone intake might be due to unbalanced patient rando-
mization regarding a specific patient’s covariates between the
different groups, causing higher amiodarone steady-state expo-
sures in the 2-week washout patients. The examination of avail-
able covariates (body weight, height, sex, age, race, or creatinine
clearance) did not allow for finding any differences between
groups. The potentially unbalanced covariate remains unknown
but, as amiodarone and dronedarone absorption, distribution,
metabolism, and excretion profiles (mainly CYP3A-mediated
clearance) are similar, this unknown covariate seems to be also
involved in the higher exposures of dronedarone in the 2-week
washout patients. The effect of this possible unknown covari-
ate—which could be a pharmacogenomic polymorphism of
metabolizing enzymes such as CYP3A5*1/*3 and/or drug trans-
porters—is nevertheless not in accordance with the metabolic
ratios, which remained roughly constant whatever the consid-
ered exposure, indicating that no metabolic interaction has
occurred with dronedarone that could have explained these dif-
ferences. Of course, the observed differences between the 3
treatment groups might also be due to chance in an underpow-
ered study. While the overall safety profile also appeared to be
good in the Long-term study, few AF events were observed, and
thus no firm conclusions can be drawn on the optimal time for
initiation of dronedarone in patients with more than 6 months of
exposure to amiodarone.
A limitation of our findings is that complete enrollment was
not achieved in the Loading study due to changes in the drone-
daroneCommittee forMedicinal Products for HumanUse label-
ing required by the European Medical Agency. These changes
weremade secondary to hepatic issues (external to these studies)
and the results of the PALLAS study. However, in spite of this
limitation, the results of both studies suggest that immediate
switching from amiodarone to dronedarone, after amiodarone
loading or long-term treatment with amiodarone, is not associ-
ated with an increased rate of arrhythmic recurrences or major
AEs, including the necessity of drug discontinuation, QTc inter-
val prolongation, or drug-induced bradycardia. These findings
are further supported by Immordino et al, inwhich a rapid switch
from amiodarone to dronedarone within a 2-day time frame was
associated with a low overall incidence of AEs and appeared
feasible in certain categories of patients with AF. Although this
trial demonstrated that a rapid switch from amiodarone to dro-
nedarone appeared safe, there were slightly more bradyarrhyth-
mic and heart failure events.
High-risk patients with heart rates <50 bpm, QTcB >500
milliseconds, or a PR >280 milliseconds were excluded from
the trial, similar to previous trials and according to the package
insert for dronedarone. Therefore, our findings should not be
extrapolated to these high-risk patients. In addition, although
heart failure patients were included in the trial, high-risk
patients with heart failure were excluded and findings from
this study should not be extrapolated to these high-risk patients.
Conclusion
Based on the data presented here, immediate switching from
amiodarone to dronedarone, after amiodarone loading or long-
term treatment with amiodarone, appears to be well tolerated
after both loading dose and long-term amiodarone use. How-
ever, due to the low number of patients in the Loading study as
a result of the premature study discontinuation, and given that
the Long-term study was not powered for efficacy/safety, any
conclusions may be limited. As such, any decisions regarding
switching between 1 drug and another should be made by the
treating physician and taken on a case-by-case basis, consider-
ing the individual patients’ characteristics.
Appendix
Table 1. Enrollment Summary by Country and Site—Randomized
Population. ARTEMIS Loading Dose Study.
Randomized (n, %)
Total
(N ¼ 176)
Immediate
dronedarone
(n ¼ 58)
2 weeks of
washout
(n ¼ 59)
4 weeks of
washout
(n ¼ 59)
Australia 5 (8.6) 6 (10.2) 6 (10.2) 17 (9.7)
Site 002 4 (6.9) 4 (6.8) 4 (6.8) 12 (6.8)
Site 005 0 2 (3.4) 1 (1.7) 3 (1.7)
Site 011 1 (1.7) 0 1 (1.7) 2 (1.1)
Austria 2 (3.4) 2 (3.4) 2 (3.4) 6 (3.4)
Site 001 0 0 1 (1.7) 1 (0.6)
Site 002 1 (1.7) 1 (1.7) 0 2 (1.1)
Site 004 0 0 1 (1.7) 1 (0.6)
Site 007 1 (1.7) 1 (1.7) 0 2 (1.1)
(continued)
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Table 1. (continued)
Randomized (n, %)
Total
(N ¼ 176)
Immediate
dronedarone
(n ¼ 58)
2 weeks of
washout
(n ¼ 59)
4 weeks of
washout
(n ¼ 59)
Estonia 5 (8.6) 5 (8.5) 5 (8.5) 15 (8.5)
Site 001 5 (8.6) 5 (8.5) 5 (8.5) 15 (8.5)
Finland 2 (3.4) 1 (1.7) 1 (1.7) 4 (2.3)
Site 001 1 (1.7) 0 0 1 (0.6)
Site 002 0 0 1 (1.7) 1 (0.6)
Site 004 1 (1.7) 1 (1.7) 0 2 (1.1)
France 1 (1.7) 1 (1.7) 1 (1.7) 3 (1.7)
Site 003 0 1 (1.7) 0 1 (0.6)
Site 006 1 (1.7) 0 1 (1.7) 2 (1.1)
Germany 5 (8.6) 6 (10.2) 6 (10.2) 17 (9.7)
Site 003 0 0 1 (1.7) 1 (0.6)
Site 005 2 (3.4) 4 (6.8) 3 (5.1) 9 (5.1)
Site 007 1 (1.7) 1 (1.7) 1 (1.7) 3 (1.7)
Site 010 2 (3.4) 1 (1.7) 1 (1.7) 4 (2.3)
Italy 6 (10.3) 6 (10.2) 6 (10.2) 18 (10.2)
Site 001 1 (1.7) 2 (3.4) 2 (3.4) 5 (2.8)
Site 003 0 1 (1.7) 0 1 (0.6)
Site 004 1 (1.7) 0 0 1 (0.6)
Site 005 0 1 (1.7) 1 (1.7) 2 (1.1)
Site 009 4 (6.9) 2 (3.4) 3 (5.1) 9 (5.1)
Republic of
Korea
9 (15.5) 8 (13.6) 8 (13.6) 25 (14.2)
Site 001 1 (1.7) 0 1 (1.7) 2 (1.1)
Site 002 0 2 (3.4) 2 (3.4) 4 (2.3)
Site 003 0 2 (3.4) 1 (1.7) 3 (1.7)
Site 004 2 (3.4) 2 (3.4) 1 (1.7) 5 (2.8)
Site 005 3 (5.2) 1 (1.7) 1 (1.7) 5 (2.8)
Site 006 3 (5.2) 1 (1.7) 2 (3.4) 6 (3.4)
Mexico 2 (3.4) 2 (3.4) 1 (1.7) 5 (2.8)
Site 009 1 (1.7) 0 0 1 (0.6)
Site 011 0 1 (1.7) 1 (1.7) 2 (1.1)
Site 012 0 1 (1.7) 0 1 (0.6)
Site 013 1 (1.7) 0 0 1 (0.6)
The Netherlands 3 (5.2) 4 (6.8) 4 (6.8) 11 (6.3)
Site 001 1 (1.7) 0 1 (1.7) 2 (1.1)
Site 004 2 (3.4) 4 (6.8) 3 (5.1) 9 (5.1)
Portugal 0 1 (1.7) 0 1 (0.6)
Site 001 0 1 (1.7) 0 1 (0.6)
Spain 7 (12.1) 6 (10.2) 7 (11.9) 20 (11.4)
Site 001 1 (1.7) 1 (1.7) 1 (1.7) 3 (1.7)
Site 002 0 1 (1.7) 0 1 (0.6)
Site 006 2 (3.4) 0 1 (1.7) 3 (1.7)
Site 007 1 (1.7) 2 (3.4) 0 3 (1.7)
Site 008 0 0 1 (1.7) 1 (0.6)
Site 009 3 (5.2) 1 (1.7) 2 (3.4) 6 (3.4)
Site 010 0 1 (1.7) 2 (3.4) 3 (1.7)
Taiwan 3 (5.2) 3 (5.1) 4 (6.8) 10 (5.7)
Site 001 2 (3.4) 1 (1.7) 0 3 (1.7)
Site 002 1 (1.7) 0 1 (1.7) 2 (1.1)
Site 005 0 2 (3.4) 2 (3.4) 4 (2.3)
Site 008 0 0 1 (1.7) 1 (0.6)
UK 8 (13.8) 8 (13.6) 8 (13.6) 24 (13.6)
Site 001 2 (3.4) 4 (6.8) 5 (8.5) 11 (6.3)
Site 005 5 (8.6) 1 (1.7) 3 (5.1) 9 (5.1)
Site 007 1 (1.7) 3 (5.1) 0 4 (2.3)
Table 2. Enrollment Summary by Country and Site—Randomized
Population. ARTEMIS Long-Term Study.
Randomized (n, %)
Total
(N ¼ 108)
Immediate
dronedarone
(n ¼ 37)
2 weeks of
washout
(n ¼ 38)
4 weeks of
washout
(n ¼ 33)
Colombia 2 (5.4) 3 (7.9) 2 (6.1) 7 (6.5)
Site 003 1 (2.7) 1 (2.6) 0 2 (1.9)
Site 006 1 (2.7) 2 (5.3) 2 (6.1) 5 (4.6)
Czech
Republic
11 (29.7) 10 (26.3) 9 (27.3) 30 (27.8)
Site 001 2 (5.4) 2 (5.3) 1 (3.0) 5 (4.6)
Site 002 2 (5.4) 1 (2.6) 2 (6.1) 5 (4.6)
Site 003 2 (5.4) 2 (5.3) 1 (3.0) 5 (4.6)
Site 004 0 0 1 (3.0) 1 (0.9)
Site 005 1 (2.7) 0 0 1 (0.9)
Site 006 2 (5.4) 2 (5.3) 2 (6.1) 6 (5.6)
Site 007 2 (5.4) 2 (5.3) 2 (6.1) 6 (5.6)
Site 008 0 1 (2.6) 0 1 (0.9)
Denmark 3 (8.1) 6 (15.8) 4 (12.1) 13 (12.0)
Site 001 2 (5.4) 2 (5.3) 2 (6.1) 6 (5.6)
Site 002 0 2 (5.3) 0 2 (1.9)
Site 003 1 (2.7) 2 (5.3) 2 (6.1) 5 (4.6)
France 2 (5.4) 2 (5.3) 2 (6.1) 6 (5.6)
Site 001 2 (5.4) 2 (5.3) 2 (6.1) 6 (5.6)
Germany 8 (21.6) 8 (21.1) 6 (18.2) 22 (20.4)
Site 001 2 (5.4) 3 (7.9) 2 (6.1) 7 (6.5)
Site 002 2 (5.4) 1 (2.6) 2 (6.1) 5 (4.6)
Site 003 2 (5.4) 2 (5.3) 2 (6.1) 6 (5.6)
Site 004 2 (5.4) 1 (2.6) 0 3 (2.8)
Site 005 0 1 (2.6) 0 1 (0.9)
Mexico 6 (16.2) 5 (13.2) 7 (21.2) 18 (16.7)
Site 001 2 (5.4) 1 (2.6) 2 (6.1) 5 (4.6)
Site 003 2 (5.4) 0 2 (6.1) 4 (3.7)
Site 005 0 2 (5.3) 1 (3.0) 3 (2.8)
Site 006 2 (5.4) 2 (5.3) 2 (6.1) 6 (5.6)
Spain 5 (13.5) 4 (10.5) 3 (9.1) 12 (11.1)
Site 001 0 1 (2.6) 0 1 (0.9)
Site 003 1 (2.7) 0 0 1 (0.9)
Site 005 3 (8.1) 2 (5.3) 2 (6.1) 7 (6.5)
Site 007 1 (2.7) 1 (2.6) 1 (3.0) 3 (2.8)
Naccarelli et al 11
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article. G.V.N. is a consultant for Janssen, Omeicos, Acesion, Mile-
stone, and Sanofi; and has a research grant from Janssen unrelated to
this project. D.L.B has participated in advisory boards for Cardax,
Cereno Scientific, Elsevier Practice Update Cardiology, Medscape
Cardiology, PhaseBio, PLx Pharma, and Regado Biosciences; is a
member of the Board of Directors of Boston VA Research Institute,
Society of Cardiovascular Patient Care, and TobeSoft; is Chair of the
American Heart Association Quality Oversight Committee; is on the
data monitoring committees for Baim Institute for Clinical Research
(formerly Harvard Clinical Research Institute, for the PORTICO trial,
funded by St. Jude Medical, now Abbott), Cleveland Clinic (including
for the ExCEED trial, funded by Edwards), Duke Clinical Research
Institute, Mayo Clinic, Mount Sinai School of Medicine (for the
ENVISAGE trial, funded by Daiichi Sankyo), and Population Health
Research Institute; has received honoraria from the American College
of Cardiology (Senior Associate Editor, Clinical Trials and News,
ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute
for Clinical Research (formerly Harvard Clinical Research Institute;
RE-DUAL PCI clinical trial steering committee funded by Boehringer
Ingelheim; AEGIS-II executive committee funded by CSL Behring),
Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke
Clinical Research Institute (clinical trial steering committees, includ-
ing for the PRONOUNCE trial, funded by Ferring Pharmaceuticals),
HMP Global (Editor in Chief, Journal of Invasive Cardiology), Jour-
nal of the American College of Cardiology (Guest Editor; Associate
Editor), Medtelligence/ReachMD (CME steering committees), MJH
Life Sciences, Population Health Research Institute (for the COM-
PASS operations committee, publications committee, steering com-
mittee, and USA national co-leader, funded by Bayer), Slack
Publications (Chief Medical Editor, Cardiology Today’s Interven-
tion), Society of Cardiovascular Patient Care (Secretary/Treasurer),
and WebMD (CME steering committees); has other relationships with
Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steer-
ing Committee (Chair), VA CART Research and Publications Com-
mittee (Chair); has received research funding from Abbott,
Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingel-
heim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai,
Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idor-
sia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio,
PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, and The
Medicines Company; has received royalties from Elsevier (Editor,
Cardiovascular Intervention: A Companion to Braunwald’s Heart Dis-
ease); is a site co-investigator for Biotronik, Boston Scientific, CSI, St.
Jude Medical (now Abbott), and Svelte; is a trustee for American
College of Cardiology; and has performed unfunded research for
FlowCo, Merck, Novo Nordisk, and Takeda. J.-Y.L.H. has worked
on advisory boards for Sanofi, Bayer, Boehringer Ingelheim,
Bristol-Myers Squibb, Daiichi-Sankyo, GSK, Meda, MSD, Pfizer, and
Servier. A.J.C. has worked on advisory boards and/or speaker’s
bureaus for Acesion, Actelion, AstraZeneca, Bayer, Biotronik, Boeh-
ringer Ingleheim, Boston Scientific, Bristol-Myers Squibb, ChanRX,
Daiichi-Sankyo, Gilead, GSK, InfoBionic, Incarda, Johnson & John-
son, Medtronic, Menarini, Merck, Mitsubishi, Novartis, Omeicos,
Otsuka, Pfizer, Sanofi, Servier, St. Jude Medical, Takeda, and Xen-
tion. F.L. is a consultant for Sanofi and has also worked on speaker’s
bureaus for AstraZeneca, Daiichi-Sankyo, and Merck. J.T. is a con-
sultant for and/or has worked on speaker’s bureaus for Menarini and
MSD; and has received honoraria fromMenarini, BMS, and Pfizer. J.-
M.M. and L.N.-B. are both employees of Sanofi and own stock.
Funding
The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: The study
was sponsored by Sanofi, who provided assistance with data collec-
tion. PAREXEL and Prime were funded by the sponsor.
Supplemental Material
Supplemental material for this article is available online.
ORCID iD
Gerald V. Naccarelli https://orcid.org/0000-0001-8196-4554
References
1. European Heart Rhythm Association, European Association for
Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GYH, et al.
Guidelines for the management of atrial fibrillation: the task force
for the management of atrial fibrillation of the European Society
of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429. doi:
10.1093/eurheartj/ehq278
2. Connolly SJ. Evidence-based analysis of amiodarone efficacy and
safety. Circulation. 1999;100(1):2025-2034. doi:10.1161/01.cir.
100.19.2025
3. Reiffel JA, Naccarelli GV. Antiarrhythmic drug therapy for atrial
fibrillation: are the guidelines guiding clinical practice? Clin Car-
diol. 2006;29(7):97-102. doi:10.1002/clc.4960290303
4. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-
based review of clinical indications. JAMA. 2007;298(6):
1312-1322. doi:10.1001/jama.298.11.1312
5. Piccinni C, Raschi E, Poluzzi E, et al. Trends in antiarrhyth-
mic drug use after marketing authorization of dronedarone:
comparison between Emilia Romagna (Italy) and Sweden. Eur
J Clin Pharmacol. 2013;69(6):715-720. doi:10.1007/s00228-
012-1377-4
6. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS
focused update on the management of patients with atrial fibrilla-
tion (updating the 2006 guideline): a report of the American Col-
lege of Cardiology Foundation/American Heart Association Task
Force on practice guidelines. J Am Coll Cardiol. 2011;57(1):
223-242. doi:10.1016/j.jacc.2010.10.001
7. Speth H. A Linux cluster for population pharmacokinetic analy-
ses. Int J Clin Pharmacol Ther. 2004;42(4):189-190.
8. Penugonda N, Mohmand-Borkowski A, Burke JF. Dronedarone
for atrial fibrillation: how does it compare with amiodarone?
Cleve Clin J Med. 2011;78(1):179-185. doi:10.3949/ccjm.78a.
10049
9. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for main-
tenance of sinus rhythm in atrial fibrillation or flutter. N Engl J
Med. 2007;357(5):987-999. doi:10.1056/NEJMoa054686
10. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of drone-
darone on cardiovascular events in atrial fibrillation. N Engl J
Med. 2009;360(7):668-678. doi:10.1056/NEJMoa0803778
12 Journal of Cardiovascular Pharmacology and Therapeutics XX(X)
11. Touboul P, Brugada J, Capucci A, Harry Crijns JGM, Nils E,
Stefan HH. Dronedarone for prevention of atrial fibrillation: a
dose-ranging study. Eur Heart J. 2003;24(16):1481-1487. doi:
10.1016/s0195-668x(03)00321-x
12. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral
amiodarone increases the efficacy of direct-current
cardioversion in restoration of sinus rhythm in patients with
chronic atrial fibrillation. Eur Heart J. 2000;21(1):66-73. doi:
10.1053/euhj.1999.1734
13. Friberg L. Ventricular arrhythmia and death among atrial fibrilla-
tion patients using anti-arrhythmic drugs. Am Heart J. 2018;205:
118-127. doi:10.1016/j.ahj.2018.06.018
Naccarelli et al 13
